Cite
HARVARD Citation
Pivot, X. et al. (2019). 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet. 393 (10191), pp. 2591-2598. [Online].